Rapid and quantitative detection of SARS-CoV-2 IgG antibody in serum using optofluidic point-of-care testing fluorescence biosensor

Song, Dan; Liu, Jiayao; Xu, Wenjuan; Han, Xiangzhi; Wang, Hongliang; Cheng, Yuan; Zhuo, Yuxin; Long, Feng

doi:10.1016/j.talanta.2021.122800

Cited by 29 publications

(15 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A comparison of different biosensors used to detect SARS-CoV-2 IgG ,,− is listed in Table S1. Compared with the current clinical methods including ELISA and CI, LFIA took much less time.…”

Section: Results and Discussionmentioning

confidence: 99%

Ag Nanoparticles with Ultrathin Au Shell-Based Lateral Flow Immunoassay for Colorimetric and SERS Dual-Mode Detection of SARS-CoV-2 IgG

et al. 2022

View full text Add to dashboard Cite

Immunoglobulin detection is essential for diagnosing progression of SARS-CoV-2 infection, for which SARS-CoV-2 IgG is one of the most important indexes. In this paper, Ag nanoparticles with ultrathin Au shells (∼2 nm) embedded with 4-mercaptobenzoic acid (MBA) (Ag MBA @Au) were manufactured via a ligand-assisted epitaxial growth method and integrated into lateral flow immunoassay (LFIA) for colorimetric and SERS dual-mode detection of SARS-CoV-2 IgG. Ag MBA @Au possessed not only the surface chemistry advantages of Au but also the superior optical characteristics of Ag. Moreover, the nanogap between the Ag core and the Au shell also greatly enhanced the Raman signal. After being modified with anti-human antibodies, Ag MBA @Au recognized and combined with SARS-CoV-2 IgG, which was captured by the SARS-CoV-2 spike protein on the T line. Qualitative analysis was achieved by visually observing the color of the T line, and quantitative analysis was conducted by measuring the SERS signal with a sensitivity four orders of magnitude higher (detection limit: 0.22 pg/mL). The intra-assay and inter-assay variation coefficients were 7.7 and 10.3%, respectively, and other proteins at concentrations of 10 to 20 times higher than those of SARS-CoV-2 IgG could hardly produce distinguishable signals, confirming good reproducibility and specificity. Finally, this method was used to detect 107 clinical serum samples. The results agreed well with those obtained from enzyme-linked immunosorbent assay kits and were significantly better than those of the colloidal gold test strips. Therefore, this dual-mode LFIA has great potential in clinical practical applications and can be used to screen and trace the early immune response of SARS-CoV-2.

show abstract

Section: Results and Discussionmentioning

confidence: 99%

Ag Nanoparticles with Ultrathin Au Shell-Based Lateral Flow Immunoassay for Colorimetric and SERS Dual-Mode Detection of SARS-CoV-2 IgG

et al. 2022

View full text Add to dashboard Cite

show abstract

“…All the specifications in combination with the fact that the biosensor was a miniaturized device makes it suitable for testing in point-of-care conditions. A miniaturized device with the potential to be used in point-of-care conditions was also constructed on a fluorometric principle [ 89 ]. The fluorometric assay was conceived as an optofluidic fluorescence biosensor where the S protein was the recognition part interacting with IgG in the tested sample.…”

Section: Biosensors For Measuring Anti-covid-19 Antibodiesmentioning

confidence: 99%

Progress in Biosensors for the Point-of-Care Diagnosis of COVID-19

Pohanka

2022

Sensors

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is a highly virulent infection that has caused a pandemic since 2019. Early diagnosis of the disease has been recognized as one of the important approaches to minimize the pathological impact and spread of infection. Point-of-care tests proved to be substantial analytical tools, and especially lateral flow immunoassays (lateral flow tests) serve the purpose. In the last few years, biosensors have gained popularity. These are simple but highly sensitive and accurate analytical devices composed from a selective molecule such as an antibody or antigen and a sensor platform. Biosensors would be an advanced alternative to current point-of-care tests for COVID-19 diagnosis and standard laboratory methods as well. Recent discoveries related to point-of-care diagnostic tests for COVID-19, the development of biosensors for specific antibodies and specific virus parts or their genetic information are reviewed.

show abstract

“…The strategies are applied to reduce the viral spreads. 20 Messenger RNA vaccines are first licensed for use. Although RT-PCR is very common method for the detection of corona virus.…”

Section: Detection By Antibodiesmentioning

confidence: 99%

Detection of the Coronavirus

Qadir¹,

Wajid²

2022

IJFCM

View full text Add to dashboard Cite

Corona is a single stranded RNA virus contains two subfamilies: Coronavirinae and Torovirinae. Its genome size is very larger and divided into four different strains. First autopsy material is collected from the lung tissue for the detection. The sample then stored in a sterile container at 2-8°C. The samples should be the properly labeled. Birthdate, medical record and name of patient must be mentioned. The initial cases were observed in China, Wuhan. The data collected by WHO from the patient’s admitted in ICU. On the basis of their genetic sequence, detection is done by the antibodies. Lateral immune-flow assay can detect the IgG and IgM antibodies. RT-PCR assays can detect the virus by specific primer and probe designing. Middle East Respiratory Syndrome (MERS) can be detected by real time PCR. X-ray Crystallography and Computed Tomography can be used for this purpose. Different X-rays analysis like inception, Xception and ResNeXt net are proposed for the detection.

show abstract

Rapid and quantitative detection of SARS-CoV-2 IgG antibody in serum using optofluidic point-of-care testing fluorescence biosensor

Cited by 29 publications

References 35 publications

Ag Nanoparticles with Ultrathin Au Shell-Based Lateral Flow Immunoassay for Colorimetric and SERS Dual-Mode Detection of SARS-CoV-2 IgG

Ag Nanoparticles with Ultrathin Au Shell-Based Lateral Flow Immunoassay for Colorimetric and SERS Dual-Mode Detection of SARS-CoV-2 IgG

Progress in Biosensors for the Point-of-Care Diagnosis of COVID-19

Detection of the Coronavirus

Contact Info

Product

Resources

About